BridgeBio is demonstrably advanced its development of a novel therapy for ATTR-CM, employing Attruby. Initial trial data indicates significant improvements for individuals diagnosed with a severe illness. The focus represents BridgeBio's focus to managing significant medical requirements in the cardiology field. Attruby: BridgeBio's Nov… Read More